Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 559

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 5
Chunk 559
---
 was royalty revenue attributable from in-market sales of $107.5 million);
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   An increase in sales of Sulanda to $49.0 million for the year ended December 31, 2024 from $43.9 million for the year ended December 31, 2023, offset by:
-------------------------------------------------------------------------------------------------------------------------------------------------------------
​

●   A decrease in sales of Orpathys (primarily to AstraZeneca) to $24.5 million for the year ended December 31, 2024 (of which $13.6 million was royalty revenue attributable from in-market sales of $45.5 million and $10.9 million was sales of goods) from $28.9 million for the year ended December 31, 2023 (of which $13.8 million was royalty revenue attributable from in-market sales of $46.1 million and $15.1 million was sales of goods);
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Other revenue in Oncology/Immunology decreased to $91.8 million for the year ended December 31, 2024 from $364.4 million for the year ended December 31, 2023 primarily due to:

●   A decrease in Takeda collaboration revenue to $67.0 million for the year ended December 31, 2024 (which primarily includes $30.9 million was the revenue recognized from the $400 million upfront payment, $18.9 million was related to research and development services, $14.2 million was recognized from the Europe and Japan regulatory milestones) from $345.9 million for the year ended December 31, 2023 (which primarily includes $280.0 million was revenue recognized from the upfront payment, $33.9 million related to research and development services);
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   $6.0 million milestone revenue recognized from AstraZeneca for the year ended December 31, 2024 following NDA acceptance in China for Orpathys combined with Tagrisso.
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Revenue from our Other Ventures decreased to $266.8 million for the year ended December 31, 2024 from $309.4 million for the year ended December 31, 2023, primarily due lower COVID-related prescription drug product sales and the disposal of Hutchison Hain Organic and HUTCHMED Science Nutrition in December 2023.
Cost of Revenue
Our cost of revenue decreased by